UBS Global Biopharma Conference 2026
Logotype for Olema Oncology Inc

Olema Oncology (OLMA) UBS Global Biopharma Conference 2026 summary

Event summary combining transcript, slides, and related documents.

Logotype for Olema Oncology Inc

UBS Global Biopharma Conference 2026 summary

17 Nov, 2026

OPERA-01 design and readout

  • OPERA-01, a Phase III monotherapy trial in 2L/3L metastatic breast cancer after CDK4/6 + AI, compares once-daily palazestrant with fulvestrant or exemestane; PFS is the primary endpoint, with readout expected in Q1 2027.

  • Tumors are tested for ESR1 status and patients are stratified; mutant and wild-type populations are analyzed independently, and meeting the critical value in either population would be a positive trial.

  • Management said the trial is powered to detect a clinically meaningful benefit in either population; the meaningful threshold may differ with the existing standard of care.

  • Compared with Phase II, OPERA-01 excludes prior chemotherapy for advanced/metastatic disease and requires at least 6 months without progression on prior therapy; Phase II allowed prior chemotherapy and had no progression-time cutoff.

  • Management highlighted the convenience and potential quality-of-life benefit of one daily pill versus two large-volume intramuscular injections every 28 days with fulvestrant.

Efficacy rationale and market opportunity

  • Phase II median PFS was 7.3 months in ESR1-mutant disease and 5.5 months in wild-type disease; management cited expected control-arm PFS of 2–3 months.

  • Management sees potential differentiation in mutant disease and a possible wild-type benefit, which it described as unique; cited annual market opportunities were $2B for mutant and ~$3B for wild-type disease.

  • Management said prior SERD results established activity in ESR1-mutant disease, while wild-type activity has been harder to demonstrate; OPERA-01 tests the two groups separately.

  • Management distinguished OPERA-01’s endocrine-resistant population, after CDK4/6 + AI, from endocrine-sensitive patients in OPERA-02, cautioning that outcomes in one setting may not predict the other.

First-line and future development

  • OPERA-02, a Phase III first-line study with palazestrant plus KISQALI, is enrolling well; KISQALI + AI is the control regimen and the global standard of care.

  • Management plans to assess SERENA-4 data expected in early December 2026 for a current estimate of control-arm performance; a longer-than-expected control PFS could prompt a trial modification.

  • After the OPERA-01 readout, management said an adjuvant palazestrant trial would be worth considering and that the result would help inform future strategy.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Olema Oncology